Skip to content

Pulse Biosciences

US · PLSE #2388 by market cap Listed 2016
45.55 +1.14 +2.57%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 21 in the most recent period (2026/Q3).
  • Total institutional ownership rose 0.3 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
16.54% +0.32pp
Institutions
157 +21
As of
2026/Q3 vs. prior period

Holder types

Individual/Insider68.04%
Mutual Fund9.55%
Hedge Fund3.48%
Public Company2.23%
Private Company0.96%
Sovereign Wealth Fund0.14%
Other15.43%

Top holders as of 2026-05-11

Robert Duggan 66.38% · 48.82M sh
BlackRock 2.28% · 1.67M sh
Bank of America Corporation 1.97% · 1.45M sh
Vanguard Capital Management, LLC 1.28% · 937.95K sh
Mahkam Zanganeh 1.19% · 873.47K sh
Portolan Capital Management, LLC 1.02% · 753.33K sh
T. Rowe Price Group, Inc. 1.02% · 748.64K sh
Balyasny Asset Management L.P. 0.98% · 718.10K sh
Genius Inc. 0.86% · 630.11K sh
Citadel Advisors LLC 0.85% · 626.51K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 38 buys · 12 sells

NameRoleStake
Robert Duggan Independent Co-Chairman 66.38%
Mahkam Zanganeh Independent Director 1.19%
Darrin Uecker CTO & Director 0.39%
Kevin Danahy Former Chief Commercial Officer 0.06%
Paul LaViolette President, CEO & Co-Chairman of the Board 0.02%
Liane Teplitsky Chief Operating Officer 0.01%
Richard van den Broek Independent Director --
Burke Barrett Former Chief Executive Officer --
Maria Degois-Sainz Independent Director --
Manmeet Soni Lead Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-08-31 Liane Teplitsky Chief Operating Officer Open Market Acquisition +2,025 $48.80–49.95
2026-08-27 Liane Teplitsky Chief Operating Officer Open Market Acquisition +2,070 $48.24–48.35
2026-08-07 Liane Teplitsky Chief Operating Officer Other Derivative Acquisition +200,000 --
2026-08-07 Liane Teplitsky Chief Operating Officer Other Derivative Acquisition +700,000 $19.06
2026-06-10 Richard van den Broek Independent Director Other Derivative Acquisition +38,423 $26.89
2026-06-10 Robert Duggan Independent Co-Chairman Other Derivative Acquisition +42,495 $26.89
2026-06-10 Maria Degois-Sainz Independent Director Other Derivative Acquisition +33,793 $26.89
2026-06-10 Mahkam Zanganeh Independent Director Other Derivative Acquisition +44,504 $26.89
2026-06-10 Manmeet Soni Lead Independent Director Other Derivative Acquisition +30,000 $26.89
2026-05-10 Paul LaViolette President, CEO & Co-Chairman of the Board Open Market Acquisition +15,000 $19.69
2026-05-10 Robert Duggan Independent Co-Chairman Open Market Acquisition +660,233 $19.69
2026-03-22 Darrin Uecker CTO & Director Other Derivative Acquisition +100,000 --
2026-02-17 Kevin Danahy Former Chief Commercial Officer Derivative Exercise and Sale -5,000 $1.53–23.64
2026-02-16 Kevin Danahy Former Chief Commercial Officer Derivative Exercise and Sale -60,000 $1.53–23.63
2026-02-11 Kevin Danahy Former Chief Commercial Officer Intent to Sell (Form 144) -50,000 $25.25
2026-02-10 Kevin Danahy Former Chief Commercial Officer Derivative Exercise and Sale -60,000 $1.53–25.20
2026-02-08 Kevin Danahy Former Chief Commercial Officer Intent to Sell (Form 144) -75,000 $20.75
2026-02-04 Maria Degois-Sainz Independent Director Other Derivative Acquisition +53,104 $13.69–14.72
2025-10-01 Kevin Danahy Former Chief Commercial Officer Derivative Exercise and Sale -4,600 $1.53–18.53
2025-09-18 Kevin Danahy Former Chief Commercial Officer Derivative Exercise and Sale -20,400 $1.53–18.49

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Pulse Biosciences discussion 0 comments

Add a comment